"We expect first quarter 2023 product revenue to increase between 15% and 20% compared with the first quarter of 2022," added Mr. Gudonis. "Given the strength of the patient pipeline entering 2023 – now only with reliable payers- we believe full-year product revenue growth of between 20% to 30% is attainable."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MYO:
